Explore 3 Stock Ideas & Industry Insights Download Free Report

News

Estrella Immunopharma, Inc (NASDAQ:ESLA) Stock in Focus: The Next Catalyst to Watch

● Emeryville, California-based Estrella Immunopharma develops engineered T-cell therapies for blood cancers, led by EB103, a CD19-directed candidate built on its ARTEMIS T-cell receptor platform.

Nitish Kishor | 10 September 2026

The Ticker Behind Easton Pharmaceuticals (OTC:EAPH) Now Belongs to a Different, Quieter Company

The ticker EAPH (OTC:EAPH) has indeed gone quiet, and in more ways than a flatTrading sessionsuggests. The symbol once belonged to Easton Pharmaceuticals Inc., a Toronto-based company that has since rebranded to Parallel Industries Inc. and, by available accounts, no longer conducts significant operations. …

Nitish Kishor | 10 September 2026

eHouse Global (OTC:EHOS) Deregistered From the SEC in 2016. Its Ticker Never Noticed.

eHouse Global (OTC:EHOS) is a reminder that not every ticker on a screener belongs to a living, reporting company. The stock trades at a fraction of a cent, and the entity behind it stopped filing with the U.S. Securities and Exchange Commission roughly a …

Nitish Kishor | 10 September 2026

Elite Pharmaceuticals (OTC: ELTP) Drifts Lower: Is the Pullback Creating a New Setup?

Elite Pharmaceuticals has quietly become one of the more striking turnaround stories in the generic-drug business, yet its shares have drifted lower even as the company posts record numbers. The pullback in Elite Pharmaceuticals, Inc (OTCQB: ELTP) stock stands in sharp contrast to a …

Nitish Kishor | 10 September 2026

Elicio Therapeutics (NASDAQ: ELTX) Falls: Is This a Warning Sign or a Reset?

Elicio Therapeutics has spent 2026 navigating one of the hardest stretches a clinical-stage biotech can face: a lead trial that missed its primary goal, followed by the difficult work of resetting its strategy. Against that backdrop, a single-day slide in Elicio Therapeutics, Inc (NASDAQ: …

Nitish Kishor | 10 September 2026

Elutia (NASDAQ: ELUT) Turns Lower: Why Investors Are Reassessing

A commercial-stage medical-device maker reshaping itself around a single regulatory catalyst, Elutia Inc. (NASDAQ: ELUT) has become a study in transition. The stock hovers near $0.80 with a market capitalization around $35 million after a steep year-long decline, and September finds investors weighing a …

Nitish Kishor | 10 September 2026

Embecta Corp (NASDAQ: EMBC) Slides: What Investors Need to Know

Few 2022-era spin-offs have travelled a rockier road than Embecta Corp (NASDAQ: EMBC), the diabetes-care company carved out of Becton, Dickinson. After a punishing 2026, another single-session slide has again put the maker of pen needles and syringes in focus. The move fits a …

Nitish Kishor | 10 September 2026

Emergent Health Corp (OTC:EMGE) Stopped Filing With the SEC Three Years Ago and Never Restarted

Emergent Health Corp (OTC:EMGE) is the kind of ticker that surfaces on lists of the market's lowest-priced shares, trading at a fraction of a cent with no movement in the last closing session. The harder truth is that the company has left almost no …

Nitish Kishor | 10 September 2026

Citius Pharmaceuticals, Inc (NASDAQ:CTXR) Drifts Lower: Is the Pullback Creating a New Setup?

● The recent daily decline in CTXR shares has no single identifiable public catalyst and is characteristic of a low-priced, thinly capitalized stock.

Nitish Kishor | 10 September 2026

Cuprina Holdings (NASDAQ: CUPR) Falls: Is This a Warning Sign or a Reset?

A pullback of nearly 7% in a single session has drawn eyes to Cuprina Holdings (Cayman) Limited (NASDAQ: CUPR), a newly public, Singapore-based biomedical micro-cap trading around $2.91. For a company this small, sharp swings are routine, and the recent decline does not trace …

Nitish Kishor | 10 September 2026
Support

Hi! How can we help you today?

Loading…